Western Europe Cancer Therapeutics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
No. of Pages: 150 | Report Code: BMIRE00031450 | Category: Life Sciences
No. of Pages: 150 | Report Code: BMIRE00031450 | Category: Life Sciences
The cancer therapeutics market size is expected to reach US$ 1,15,334.80 Million by 2031 from US$ 52,938.08 Million in 2024. The market is estimated to record a CAGR of 10.89 % from 2025 to 2031.
The cancer therapeutics market in Western Europe is experiencing significant growth driven by several key factors, including growing burden of breast and lung cancer and surging investments in oncology research. For instance, In October 2024, Innovate UK and the Office for Life Sciences (OLS) revealed additional support for cancer innovation. They have plans to collaboratively invest US$ 5.19 million (£4 million) in 6 projects as part of the advancing competition in precision medicine. The OLS Cancer Programme is designed to establish the UK as a premier testbed for oncology innovation by speeding up the development and commercialization of a new generation of cancer diagnostics and therapeutics.
Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.
The cancer therapeutics market in Western Europe is experiencing significant growth driven by growing burden of breast and lung cancer and surging investments in oncology research contributes significantly to overall market growth. The Western Europe cancer therapeutics market is segmented into Germany, the UK, France, Spain, Italy, Switzerland, Austria, and Portugal. The well-established healthcare infrastructure in Western European countries ensures that patients have access to the latest cancer therapies. National health systems in countries such as the UK, Germany, and France provide comprehensive cancer treatment options, further accelerating the uptake of advanced therapies. Governments and the European Union invest heavily in cancer research and drug development. Programs such as Horizon Europe and national cancer initiatives provide funding for research, clinical trials, and novel cancer therapy developments, fostering growth and innovation in the cancer therapeutics market.
Based on region, the Eastern Western Europe cancer therapeutics market is further segmented into Germany, the UK, France, Spain, Italy, Switzerland, Austria, and Portugal. The Germany held the largest share in 2024.
Cancer is one of the leading causes of morbidity and mortality in Germany; the country reports a vast number of cases of lung cancer, prostate cancer, bladder cancer, colorectum cancer, and skin cancer. According to the World Health Organization (WHO), Germany recorded ~0.63 million new cancer cases and ~0.25 million deaths in 2022. The rising number of cancer cases in Germany propels the demand for better treatment options. Moreover, Germany is a hub for cancer research, with institutions such as the German Cancer Research Center, and partnerships between such research organizations and pharmaceutical companies fostering innovation in treatment options. For instance, Germany is home to clinical trials for cutting-edge therapies such as CAR-T cell treatments and immune checkpoint inhibitors, which have revolutionized cancer care. Additionally, the Federal Ministry of Education and Research (BMBF) launched the National Decade against Cancer in 2019, which brings together medicine and research, society, politics, and business.
The country's strong biotechnology sector, bolstered by government funding and collaboration with major pharmaceutical companies, accelerates the development and commercialization of new therapeutics. In February 2024, Boehringer Ingelheim and CBmed GmbH, the Center for Biomarker Research in Medicine, unveiled a long-term strategic partnership aimed at accelerating the development of novel cancer therapies into first-in-class medicines. The collaboration seeks to transform the lives of cancer patients and supports Boehringer Ingelheim's ultimate goal of curing various types of cancer.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 52,938.08 Million |
| Market Size by 2031 | US$ 1,15,334.80 Million |
| Global CAGR (2025 - 2031) | 10.89 % |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Therapy Type
|
| Regions and Countries Covered | Western Europe
|
Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These players adopt strategies such as expansion, product innovation, and mergers and acquisitions to stay competitive in the market and offer innovative products to their consumers.
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note:
All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:
The Western Europe Cancer Therapeutics Market is valued at US$ 52,938.08 Million in 2024, it is projected to reach US$ 1,15,334.80 Million by 2031.
As per our report Western Europe Cancer Therapeutics Market, the market size is valued at US$ 52,938.08 Million in 2024, projecting it to reach US$ 1,15,334.80 Million by 2031. This translates to a CAGR of approximately 10.89 % during the forecast period.
The Western Europe Cancer Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Western Europe Cancer Therapeutics Market report:
The Western Europe Cancer Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Western Europe Cancer Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Western Europe Cancer Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Western Europe Cancer Therapeutics Market
